ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.74
-0.53%
US Tech 100
19,880.00
-2.30%
S&P 500
5,870.62
-1.32%
US Dollar vs CAD
1.41005
-0.01%
Bitcoin
91,018.99
-0.05%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Hepion Pharmaceuticals Inc (HEPA) Share Price

Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc (HEPA)

NASDAQ
0.68
0.015
(2.26%)
Closed November 16 3:00PM
Delayed by 15 minutes
0.68
0.00
(0.00%)
After Hours: 5:55PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.68
Bid
0.641
Ask
0.68
Volume
57,478
0.62 Day's Range 0.68
0.5525 52 Week Range 4.47
Market Cap
3.943M
Previous Close
0.665
Open
0.6362
Last Trade
600
@
0.68
Last Trade Time
Financial Volume
US$ 38,266
VWAP
0.665753
Average Volume (3m)
41,479
Shares Outstanding
5,799,126
Dividend Yield
-
PE Ratio
-0.08
Earnings Per Share (EPS)
-8.44
Revenue
-
Net Profit
-48.93M

About Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and... Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.hepion.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Hepion Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HEPA. The last closing price for Hepion Pharmaceuticals was US$0.67. Over the last year, Hepion Pharmaceuticals shares have traded in a share price range of US$ 0.5525 to US$ 4.47.

Hepion Pharmaceuticals currently has 5,799,126 shares outstanding. The market capitalization of Hepion Pharmaceuticals is US$3.86 million. Hepion Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.08.

Ask ADVFN Intelligence (AI)

HEPA Latest News

More News

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination...

November 11 2024
GlobeNewswire Inc.

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination...

September 04 2024
GlobeNewswire Inc.

Form 425 - Prospectuses and communications, business combinations

August 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 07 2024
Edgar (US Regulatory)

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...

July 22 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 21 2024
Edgar (US Regulatory)

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

May 15 2024
Edgar (US Regulatory)

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...

April 19 2024
GlobeNewswire Inc.

Form 8-K - Current report

February 16 2024
Edgar (US Regulatory)

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic...

February 16 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.03956.167056986730.64050.680.62283330.6433289CS
40.00240.3541912632820.67760.8360.6483670.71590485CS
12-0.141-17.17417783190.8210.890.555414790.71593851CS
26-0.65-48.87218045111.331.360.5525984970.82469904CS
52-2.28-77.0270270272.964.470.5525844351.50228379CS
156-28.52-97.671232876729.229.80.552525369915.50595224CS
260-53.72-98.7554.41670.552596144644.46462967CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
US$ 0.2853
(52.40%)
1.17B
CYCNCyclerion Therapeutics Inc
US$ 2.5306
(42.97%)
11.99M
SPPLSIMPPLE Ltd
US$ 1.2503
(41.60%)
165.69M
PULMPulmatrix Inc
US$ 6.5586
(39.54%)
5.37M
ZTEKZentek Ltd
US$ 1.2574
(29.96%)
309.67k
TFFPTFF Pharmaceuticals Inc
US$ 0.376101
(-76.49%)
9.23M
EYENEyenovia Inc
US$ 0.10185
(-70.05%)
51.98M
CTXRCitius Pharmaceuticals Inc
US$ 0.1974
(-39.89%)
11.15M
VVPRVivoPower International PLC
US$ 0.8151
(-39.62%)
2.3M
IPWiPower Inc
US$ 0.7302
(-39.15%)
1.13M
CEROCERo Therapeutics Holdings Inc
US$ 0.2853
(52.40%)
1.15B
ELABElevai Labs Inc
US$ 0.0211
(-19.47%)
377.69M
NVDANVIDIA Corporation
US$ 141.98
(-3.26%)
244.07M
SPPLSIMPPLE Ltd
US$ 1.2503
(41.60%)
164.49M
STISolidion Technology Inc
US$ 0.44
(25.71%)
139.46M

HEPA Discussion

View Posts
tw0122 tw0122 4 weeks ago
HEPA give it a holler .85 + 40%
👍️0
blue finch blue finch 3 months ago
i remember you from vitra
we all
made money
👍️0
Ruffieruff Ruffieruff 3 months ago
Yup. Seem to find em all.
👍️0
blue finch blue finch 3 months ago
ugh
Another scam
WTF
👍️0
Monksdream Monksdream 3 months ago
HEPA new 52 week low
👍️0
Monksdream Monksdream 4 months ago
HEPA new 52 week low
👍️0
Monksdream Monksdream 4 months ago
HEPA new 52 week low
👍️0
Ruffieruff Ruffieruff 4 months ago
Scam. All shareholders continues to get screwed.
👍️0
Monksdream Monksdream 4 months ago
Whoops, I did it, again
👍️0
Awl416 Awl416 4 months ago
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
👍️0
Monksdream Monksdream 4 months ago
HEPA under $2
👍️0
Monksdream Monksdream 4 months ago
HEPA under $2
👍️0
Awl416 Awl416 7 months ago
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
👍️0
Monksdream Monksdream 9 months ago
HEPA new 52 week low
👍️0
Monksdream Monksdream 10 months ago
HEPA new 52 week low
👍️0
Ruffieruff Ruffieruff 1 year ago
POS
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 year ago
Any thoughts on whether they could see accelerated approval now? results were good and there are no good alternatives.
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 year ago
What if it is a lush partnership instead?
👍️0
shurtha2000 shurtha2000 1 year ago
Thanks
👍️0
Disquisition Disquisition 1 year ago
Absolutely correct, sir
👍️0
make it happen make it happen 1 year ago
Don't forget it's a delinquent stock has failed to meet requirements ie r/s to raise more funds rinse and repeat for at least another 3 years and if one bad thing happens expect a 90% haircut immediately imho
👍️0
Disquisition Disquisition 1 year ago
people DUMPING knowing the OFFERING is imminent…
👍️0
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 year ago
GOOD CALL: after R/S This could be a moon shot on good top line results
👍️0
da_stock_analyst da_stock_analyst 1 year ago
#HEPA ?? 117% move today! Looking strong and ready for tomorrow! $HEPA
👍️0
make it happen make it happen 1 year ago
R/S, huge double digit negative returns, burning capital, zero Profitability

Management Effectiveness
Return on Assets -42.63%
Return on Equity  -78.41%

Cash Flow Statement
Operating Cash Flow -33.05M
Levered Free Cash Flow -16.86M

Profitability
Profit Margin. 0.00%
Operating Margin 0.00%

Yahoo

It is losing/spending more than its market cap. Imho will fade back to singles and dilute. It can't keep operations running without selling shares to share holders.
👍️0
Disquisition Disquisition 1 year ago
Yes (for up to $350 million)

and Yes (check the latest 10Q - very little cash left on hand)
👍️0
TheFinalCD TheFinalCD 1 year ago
DO THEY HAVE A SHELF OFFERING TO DRAW FROM?

ARE THEY CURRENTLY IN NEED OF CASH FROM AN OFFERING?

Message in reply to:
Offering tonight or tomorrow. Called it
👍️0
TheFinalCD TheFinalCD 1 year ago
GOOD CALL
after R/S This could be a moon shot on good top line results
👍️ 1
Pt3 Pt3 1 year ago
Call wrong baby ....Biden say No more offering.... inflation is extremely now
👍️0
Disquisition Disquisition 1 year ago
Offering tonight or tomorrow. Called it
👍️0
Triple nickle Triple nickle 1 year ago
Might jus do it
👍️0
Triple nickle Triple nickle 1 year ago
Gotta bust thru 16.40 and hold it
👍️0
makinezmoney makinezmoney 1 year ago
$HEPA : Meeting those PRIMARY ENDPOINTS


Another MDGL kinda booster about to happen here.... now $15



GO $HEPA
👍️0
Ruffieruff Ruffieruff 1 year ago
This is not even .80c PS. Whose selling?
👍️0
shurtha2000 shurtha2000 1 year ago
$15.73 building a new base
👍️0
Disquisition Disquisition 1 year ago
DUMPED all my 7zzzz at 16
👍️0
shurtha2000 shurtha2000 1 year ago
Achieves primary and secondary endpoints its all good

https://finance.yahoo.com/news/hepion-pharmaceuticals-phase-2-altitude-110000500.html
👍️0
shurtha2000 shurtha2000 1 year ago
Will Pre-market trading be suspended ?
👍️0
tw0122 tw0122 1 year ago
830 am
Monday’s conference call update
👍️0
shurtha2000 shurtha2000 1 year ago
after R/S This could be a moon shot on good top line results
👍️ 1
Ruffieruff Ruffieruff 2 years ago
But it all. Taking knife. We are scammed.
👍️ 1
makinezmoney makinezmoney 2 years ago
$HEPA: So the RS happened........ now $9

But on a downdip........... will have to get some more if this dips sub $9


GO $HEPA
👍️0
Ruffieruff Ruffieruff 2 years ago
Your shares look like crap like the rest of us!! Pumper
👍️ 1
Ruffieruff Ruffieruff 2 years ago
Scumbags!!
👍️ 1
blue finch blue finch 2 years ago
I'd consider getting back at .36
👍️0
blue finch blue finch 2 years ago
Why
👍️0
Ruffieruff Ruffieruff 2 years ago
Good thing you dumped this dog.
👍️0
Ruffieruff Ruffieruff 2 years ago
Pumper come back. Where have you been? We need another boost and lecture. Pumper rah rah rah.
👍️0
Ruffieruff Ruffieruff 2 years ago
This is dogchit!!
👍️0
Ruffieruff Ruffieruff 2 years ago
Just added some SAB members. Lets see if we finally get some real info.
👍️0

Your Recent History

NASDAQ
HEPA
Hepion Pharmaceuticals
LSE
SCF
Schroder Income Growth
USOTC
CTBG
Coil Tubing Technology (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved